Theralase Technologies Inc. V.TLT

Just asking for numbers.

[Maxcitrac]

On this board the debbie downers(bashers) are almost exclusively talking about the SP & financing.

Right now the SP and financing have nothing to do with the BTD submission and approval, that everybody is anxiously waiting for.
You have to remember that when the FDA did delay the BTD process, it was not because there was something wrong about TLT treatment.
No! The FDA was simply asking for extra data, and extra data are just numbers.
The fact that the FDA was asking just for extra data, indicate that the FDA has already ackhowledged that there is nothing wrong about TLT treatment.

The extra data have been provided to the FDA, the next step has to be BTD submission and approval.
Instead of concentrating on the SP and financing,leave that to management, concentrate on the fact that the BTD approval is almost in the bag.

[chry200030]

That is correct.  I wouldn't want to be a seller right now. We are on the cusp of a nice move in share price. .25 for the cure for cancer... Really !

[CAinPlap]

So how does Roger sell a .30 pp when we are at .25? I know you have to strike while the iron is hot but going to be a tough sell.

[DJDawg]

Here's how the math works, I think. Let's say you are accredited investor and have 50k free First if you wanted to buy 200,000 shares at 0.25, not sure that would be doable. Your order would not be filled at 0.25. There is not enough on the ask. Looking at 2nd order orders at moment, buying 200k shares at market would fill the ask all the way to 0.34. If you do take the 50k and buy 167k

[CAinPlap]

Thanks Dawg for the reply. If only we could guarantee a future price above .50. Think we should already be there but given how hard it has been to get any wind in our sails, it seems so far away still. Last weeks action appears orchestrated to try and get PP terms more favorable to TLT. Would be nice to know who and why was buying last Monday.

[Longholder99]

Nice explanation Dawg and gives good perspective why there is selling now to free up money and get in on this hopefully last small PP.  If you don't have the cash to participate this is a nice chance to scoop a few shares on the cheap while those with the bigger dollars take the opportunity  

[Maxcitrac]

CAinPLap, good point. The email said financing close early November, what happen to the SP if TLT management announce that they have received the green light for BTD submission before the financing close? The SP could go over 0.30$ and maybe over the 0.38$ hight. Early November, plenty of time for the FDA giving the green light for the BTD submission.

[toade1313]

I do believe the SP relates directly to the BTD process. The pre-BTD was submitted in the first few days of October and has been stated the turnaround time is about 15 days. In my opinion the fact that there has been no anouncement of a formal BTD application means Theralase has not received the 'goahead' as of yet. Without the goahead to file the BTD, the SP will react. Also in my opinion

[Eoganacht]

The FDA advised Theralase that a BTD application would have a better chance of approval if it included longer term patient data and verified all data at a central pathology lab. Some have accused the FDA of moving the goal posts in the middle of the trial. But I think there is a reasonable explanation for why they have advised Theralase to submit the extra data.  When the Ruvidar PDT

[CAinPlap]

I have always wondered how the approval of the therapies you mentioned affected our ability to say there is an unmet need. Our inability to complete the trial in a timely manner has compunded our wait time and decreased likelyhood of BTD/AA. I also feel the "dirty dozen" undertreated patients has affected our credibility with both potential patients and the powers that be.

[Eoganacht]

I've wondered about that too. But we are better than the approved alternatives especially when you take into account safety and number of treatments. We're a more patient friendly treatment and that seems to be an increasingly important consideration going by recent urologist discussion videos. In my view we have a very high likelihood of BTD despite the increased competition.

[DJDawg]

IBRX doesn't seem to be selling much anktiva based on last financials. So you could argue that urologists are saying that that medication doesn't meet their needs. Plus anktiva needs BCG which is in short supply to start with. Adstiladrin is made by private company with no financials out. So hard to guess the sales. But I doubt that they are that great judging but DOR for the drug. So

[CancerSlayer]

Good points... In a nutshell, you enhance the care of patients by utilizing agreed upon treatments (i.e. data-driven acceptance by the IBCG, AUA, EUA) that are  not only evidence-based, but can also be "practically" used in the outpatient care setting.  The latter requires that your option be simple, cost-effective, fit into/complement current workflows, & be "both

[Dumbeldorfwhite]

Been saying this for forever yet when I said it everyone tried dragging me through the mud. It's a complete failure of leadership and as such the board should act accordingly, unfortunately there are conflict of interests. They are so far behind, enrollment is ultra slow. So many missed deadlines. And all this will absolutely kill valuation. I mean how could they ever bring any of this to